Skip to main content
. 2023 Apr 1;17(4):904–914. doi: 10.1007/s12072-023-10491-3

Fig. 2.

Fig. 2

Kaplan–Meier curve showing progression-free survival (months) for overweight (BMI ≥ 25) and non-overweight (BMI < 25) patients with unresectable hepatocellular carcinoma patients after atezolizumab plus bevacizumab administration